These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 7794217)

  • 1. Serotonin and drug-induced movement disorders.
    Sachdev P
    Aust N Z J Psychiatry; 1994 Dec; 28(4):695-6. PubMed ID: 7794217
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-induced movement disorders.
    Gershanik OS
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):369-76. PubMed ID: 8099509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neuroleptics and serotonin].
    Hery F; Hamon M
    Encephale; 1993; 19(5):525-32. PubMed ID: 7905821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].
    Guise S; Soubrouillard C; Blin O
    Encephale; 1997 Apr; 23 Spec No 2():10-6. PubMed ID: 9273300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional consequences of dopaminergic degeneration in Parkinson's disease.
    Tedroff JM
    Adv Neurol; 1999; 80():67-70. PubMed ID: 10410704
    [No Abstract]   [Full Text] [Related]  

  • 6. Neurobiological aspects of social anxiety disorder.
    Furmark T
    Isr J Psychiatry Relat Sci; 2009; 46(1):5-12. PubMed ID: 19728568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in understanding the neural mechanisms underlying L-DOPA-induced dyskinesia.
    Brotchie JM
    Adv Neurol; 1999; 80():71-85. PubMed ID: 10410705
    [No Abstract]   [Full Text] [Related]  

  • 8. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys.
    Blanchet PJ; Gomez-Mancilla B; Bédard PJ
    J Neural Transm Suppl; 1995; 45():103-12. PubMed ID: 8748615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat.
    Taylor JL; Bishop C; Walker PD
    Pharmacol Biochem Behav; 2005 Aug; 81(4):887-93. PubMed ID: 16023708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of antipsychotic drug-induced movement disorders.
    Casey DE
    J Clin Psychiatry; 2004; 65 Suppl 9():25-8. PubMed ID: 15189109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoaminergic regulation of brain somatostatin metabolism in rats.
    Maeda K; Kakigi T; Kawata E; Kaneda H
    Jpn J Psychiatry Neurol; 1991 Mar; 45(1):109-10. PubMed ID: 1684392
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
    Bédard PJ; Gomez-Mancilla B; Blanchette P; Gagnon C; Falardeau P; DiPaolo T
    Adv Neurol; 1993; 60():113-8. PubMed ID: 8093573
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
    Rascol O; Brefel-Courbon C; Descombes S; Montastruc JL
    Adv Neurol; 1999; 80():485-90. PubMed ID: 10410760
    [No Abstract]   [Full Text] [Related]  

  • 15. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D2-like receptors and the antidepressant response.
    Gershon AA; Vishne T; Grunhaus L
    Biol Psychiatry; 2007 Jan; 61(2):145-53. PubMed ID: 16934770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications.
    Ba M; Kong M; Ma G; Yang H; Lu G; Chen S; Liu Z
    Brain Res; 2007 Jan; 1127(1):177-84. PubMed ID: 17113046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.
    Carta M; Carlsson T; Muñoz A; Kirik D; Björklund A
    Prog Brain Res; 2008; 172():465-78. PubMed ID: 18772046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of dopamine receptors.
    Jarvie KR; Caron MG
    Adv Neurol; 1993; 60():325-33. PubMed ID: 8380525
    [No Abstract]   [Full Text] [Related]  

  • 20. [Neurobiology in the neuropharmacology of antipsychotic drugs].
    Tassin JP
    Encephale; 2006 Jan; 32 Pt 2():S6-7. PubMed ID: 16800077
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.